These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 15222613)

  • 41. Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome.
    Leenen FH
    Can J Cardiol; 2004 Aug; 20 Suppl B():77B-82B. PubMed ID: 15309209
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapeutic implications of recent megatrials: in favor of old drugs.
    Salvetti A; Salvetti G; Cipriano A; Virdis A; Ghiadoni L
    J Nephrol; 2007; 20 Suppl 12():S4-S11. PubMed ID: 18050142
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension.
    Mancia G; De Backer G; Dominiczak A; Cifkova R; Fagard R; Germano G; Grassi G; Heagerty AM; Kjeldsen SE; Laurent S; Narkiewicz K; Ruilope L; Rynkiewicz A; Schmieder RE; Boudier HA; Zanchetti A;
    J Hypertens; 2007 Sep; 25(9):1751-62. PubMed ID: 17762635
    [No Abstract]   [Full Text] [Related]  

  • 44. Managing hypertension in high-risk patients: lessons and promises from the STRATHE and ADVANCE trials.
    Waeber B
    J Hypertens Suppl; 2006 May; 24(3):S19-27. PubMed ID: 16723862
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of ASCOT on hypertension treatment and guidelines in older adults.
    Sheridan R; Baldwin N
    Age Ageing; 2006 May; 35(3):214-7. PubMed ID: 16638764
    [No Abstract]   [Full Text] [Related]  

  • 46. Improvement of blood pressure control in hypertensive patients with renal diseases.
    Ohta Y; Tsuruya K; Fujii K; Tokumoto M; Kanai H; Matsumura K; Tsuchihashi T; Hirakata H; Iida M
    Hypertens Res; 2007 Apr; 30(4):295-300. PubMed ID: 17541207
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The 2007 ESH/ESC guidelines for the management of arterial hypertension.
    Bonny A; Lacombe F; Yitemben M; Discazeaux B; Donetti J; Fahri P; Megbemado R; Estampes B
    J Hypertens; 2008 Apr; 26(4):825; author reply 825-6. PubMed ID: 18327095
    [No Abstract]   [Full Text] [Related]  

  • 48. The future of antihypertensive treatment.
    Israili ZH; Hernández-Hernández R; Valasco M
    Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 1989 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting.
    Bull World Health Organ; 1989; 67(5):493-8. PubMed ID: 2611974
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Hypertension combination therapy with renin-angiotensin system blockers].
    Soucek M
    Vnitr Lek; 2009 Sep; 55(9):719-23. PubMed ID: 19785368
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pathologic basis and treatment considerations in chronic kidney disease-related hypertension.
    Sica D; Carl D
    Semin Nephrol; 2005 Jul; 25(4):246-51. PubMed ID: 16202697
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Do beta-blockers prevent coronary events in hypertensive patients?].
    Diévart F; Ragot S; Julien J; Herpin D
    Arch Mal Coeur Vaiss; 2005 Sep; 98(9):881-8. PubMed ID: 16231574
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New onset diabetes during antihypertensive therapy.
    Alderman MH
    Am J Hypertens; 2008 May; 21(5):493-9. PubMed ID: 18437139
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Arterial hypertension and hypertensive cardiopathy at the turn of the millenium].
    González-Juanatey JR
    Rev Esp Cardiol; 1999; 52 Suppl 3():1-3. PubMed ID: 10614143
    [No Abstract]   [Full Text] [Related]  

  • 57. [Treatment of arterial hypertension. Re-emergence of diuretics].
    Guelpa G
    Praxis (Bern 1994); 1995 Nov; 84(46):1356-7. PubMed ID: 7491466
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Determining hypertensive end-organ damage in trials: a review of current methodologies and techniques.
    Birkenhäger WH; de Leeuw PW
    J Cardiovasc Pharmacol; 1992; 19 Suppl 5():S43-50. PubMed ID: 1381794
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 1999 WHO/ISH Hypertension Guidelines--highlights & ESH Update.
    Kjeldsen SE; Erdine S; Farsang C; Sleight P; Mancia G
    Blood Press; 2003; 12(3):181-2. PubMed ID: 12875481
    [No Abstract]   [Full Text] [Related]  

  • 60. [Clinical evaluation of the diuretic and hypotensive action of certain preparations].
    Merkur'ev ND; Parakhnevich DT; Slepynin VI; Sokolov VI
    Voen Med Zh; 1974 Jan; (1):75-7. PubMed ID: 4617411
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.